Purpose | Dosage | Frequency | Administration |
---|---|---|---|
General Anxiety | 300-900 mcg | 1-3x daily | Intranasal |
Cognitive Enhancement | 300-600 mcg | 1-2x daily | Intranasal |
Stress Management | 300-900 mcg | 1-3x daily | Intranasal |
Research | 250-1000 mcg | 1-3x daily | Intranasal/Subcutaneous |
Selank is a synthetic peptide drug developed in Russia. Key points:
Composed of the tuftsin sequence (Thr-Lys-Pro-Arg) with an added Pro-Gly-Pro at the C-terminus
Molecular formula: C33H55N11O9
Molecular weight: 751.86 g/mol
Developed by the Institute of Molecular Genetics of the Russian Academy of Sciences
Approved for medical use in Russia for anxiety disorders
Known for its anxiolytic and nootropic properties
Binds to GABA receptors, potentially modulating GABAergic neurotransmission
Increases serotonin metabolism and affects serotonergic system
Elevates brain-derived neurotrophic factor (BDNF) levels
Modulates expression of interleukin-6 (IL-6) and other cytokines
Affects balance of T helper cell cytokines
Influences concentration of monoamine neurotransmitters (dopamine, norepinephrine)
May interact with enkephalins and affect opioid system
Reduces symptoms of generalized anxiety disorder
May help with panic disorders and social anxiety
Shows efficacy comparable to benzodiazepines without side effects
Improves learning and memory
Enhances attention and mental clarity
May have neuroprotective effects
Increases stress resilience
May help normalize sleep patterns
Potential adaptogenic properties
Affects cytokine production
May enhance natural killer cell activity
Potential antiviral properties
Shows antidepressant-like effects in animal models
May enhance the effects of traditional antidepressants
Typical dose: 300-900 mcg per day
Often divided into 1-3 doses
Start with lower dose and titrate up as needed
Typical dose: 300-600 mcg per day
Usually administered 1-2 times daily
May be used as needed for acute cognitive boost
Dose range: 300-900 mcg per day
Can be administered 1-3 times daily
May be used acutely before stressful events
Dose range: 250-1000 mcg per day
Frequency depends on research protocol
Higher doses may be used for specific studies
If using lyophilized powder, reconstitute with bacteriostatic water or saline
Use 1 ml of water per 10 mg of Selank powder
Gently swirl to mix, avoid shaking
Calculate dosage based on concentration (e.g., 0.15% solution = 150 mcg per drop)
Most common method
Tilt head back slightly
Insert dropper or spray nozzle into nostril
Administer prescribed dose
Allow solution to absorb through nasal mucosa
Use insulin syringe (29-31 gauge)
Inject into fatty tissue of abdomen or thigh
Rotate injection sites
May enhance cognitive effects of racetams
Potential synergy with cholinergic compounds
May potentiate effects of SSRIs
Could reduce side effects of traditional antidepressants
May enhance effects of anxiolytic herbs (e.g., ashwagandha)
Potential to reduce required dose of benzodiazepines
Selank is available through specialized pharmacies in Russia. For research purposes, it may be obtained from reputable peptide suppliers. Always ensure third-party testing and proper documentation.
No significant side effects reported in clinical trials
No addiction or withdrawal symptoms observed
Does not impair cognitive function or motor skills
Nasal irritation (with intranasal use)
Mild headache
Dizziness (rare)
Approved for medical use in Russia
Not approved by FDA or EMA for human use
Legal status varies by country
Often available as a research chemical, not for human consumption
Not controlled under the Controlled Substances Act in the US
Store lyophilized powder at room temperature (20-25°C or 68-77°F)
Once reconstituted, store in refrigerator (2-8°C or 36-46°F)
Use within 30 days after reconstitution
Protect from light and excessive heat
Keep out of reach of children
Effects may be noticeable within 5-15 minutes of administration, with peak effects occurring within 2-3 hours.
While some studies have used Selank for up to 3 months, long-term safety data is limited. Consult a healthcare professional for extended use.
Unlike benzodiazepines, Selank is not associated with sedation or drowsiness, making it suitable for daytime use.
While some research suggests potential antidepressant effects, Selank is primarily studied for anxiety. More research is needed for its use in depression.
Selank shows promise as an anxiolytic and nootropic peptide with a favorable safety profile compared to traditional anxiety medications. The typical dosage range of 300-900 mcg per day, depending on the application, appears effective for most research purposes. Its unique mechanism of action, combining anxiolytic effects with potential cognitive enhancement, makes it an intriguing subject for further study.However, its use should be approached cautiously due to limited long-term safety data and varying legal status worldwide. As with any experimental compound, thorough research and professional consultation are essential before use. The potential of Selank in anxiety disorders, cognitive enhancement, and stress management warrants further investigation, particularly in larger, long-term human trials.
Kozlovskaya MM, et al. (2003). Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Neuroscience and Behavioral Physiology, 33(9), 853-860.
Kolomin T, et al. (2013). Transcriptomic effects of tuftsin-like peptides in the hippocampus of rats. Molecular Genetics and Genomics, 288(7-8), 353-360.
Medvedev VE, et al. (2015). Optimization of the treatment of anxiety disorders with selank. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 115(6), 33-40.
Semenova TP, et al. (2008). Experimental study of effects of selank on learning and memory. Bulletin of Experimental Biology and Medicine, 145(5), 569-572.
Eremin KO, et al. (2005). Influence of Semax on the level of monoamines and their metabolites in the brain of rats with different phenotypes of emotional and stress response. Bulletin of Experimental Biology and Medicine, 139(5), 523-526.
Ashmarin IP, et al. (2008). Natural and hybrid ("chimeric") stable regulatory glyproline peptides. Pathophysiology, 15(3), 203-209.
Volkova A, et al. (2016). Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology, 7, 31.
Czabak-Garbacz R, et al. (2006). Influence of long-term treatment with tuftsin analogue TP-7 on the anxiety-phobic states and body weight. Pharmacological Reports, 58(4), 562-567.
Telegina DV, et al. (2013). Influence of Selank on Systems of GABA and Serotonin in the Rat Brain. Bulletin of Experimental Biology and Medicine, 155(3), 335-337.
Kolik LG, et al. (2012). Anxiolytic effects of selank in different animal models of anxiety. Bulletin of Experimental Biology and Medicine, 152(3), 335-338.
Disclaimer
Peptideresearcher.com contains information about products intended for research and laboratory use only, unless otherwise explicitly stated. All content is for educational purposes and is not meant to substitute for professional medical advice. Peptideresearcher.com strives to ensure that all information presented is accurate and complies with national and international standards, but it is not guaranteed. The content provided is not intended to diagnose, treat, cure, or prevent any disease or condition.
Peptideresearcher.com does not offer medical diagnoses or prescriptions. Any product information shared is solely for research purposes and should be used by qualified professionals only. We advise all users to consult with a healthcare professional before using any peptides, supplements, or medications mentioned on this site. All opinions expressed are those of the individual authors and may not reflect the opinions of Peptideresearcher.com.
Copyright 2024 - Peptide Researcher
Your access to Peptideresearcher.com is subject to our Terms of Use